Does levodopa slow or hasten the rate of progression of Parkinson’s disease?
暂无分享,去创建一个
[1] Claude Nahmias,et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study , 2003, Annals of neurology.
[2] M. Brin,et al. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.
[3] Y. Agid,et al. Does levodopa aggravate Parkinson's disease? , 1988, Neurology.
[4] W. Dauer,et al. Parkinson's Disease Mechanisms and Models , 2003, Neuron.
[5] A. E. Lang,et al. Practice parameter: Initiation of treatment for Parkinson’s disease: An evidence-based review , 2002, Neurology.
[6] S Fahn,et al. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. , 1999, Archives of neurology.
[7] D J Brooks,et al. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. , 1996, Brain : a journal of neurology.
[8] J. Seibyl,et al. Do dopamine agonists or levodopa modify Parkinson's disease progression? , 2002, European journal of neurology.
[9] S. Fahn. Adverse Effects of Levodopa in Parkinson’s Disease , 1989 .
[10] F. Mcdowell,et al. “Early” initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease , 1991, Neurology.
[11] Niall Quinn,et al. Young onset Parkinson's disease , 1987, Movement disorders : official journal of the Movement Disorder Society.
[12] H. Hefter,et al. Is levodopa toxic? , 2004, Journal of Neurology.
[13] R Kieburtz,et al. Effect of lazabemide on the progression of disability in early Parkinson's disease , 1996, Annals of neurology.
[14] E. van der Velde,et al. Response fluctuations in Parkinson's disease , 1990, Neurology.
[15] O Rascol. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group , 2000 .
[16] C. Tanner,et al. Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.
[17] R. Albin,et al. Initial agonist treatment of Parkinson disease , 2003, Neurology.
[18] E. Schechtman,et al. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review. , 2002, Neurology.
[19] George C. Cotzias,et al. Modification of Parkinsonism--chronic treatment with L-dopa. , 1969, The New England journal of medicine.
[20] L. Schiffer,et al. Aromatic amino acids and modification of parkinsonism. , 1967, The New England journal of medicine.
[21] P. Riederer,et al. Time course of nigrostriatal degeneration in parkinson's disease , 1976, Journal of Neural Transmission.
[22] P. Czernichow,et al. Growth in Paediatric Crohn’s Disease , 2002, Hormone Research in Paediatrics.
[23] John Seibyl,et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. , 2004, Archives of neurology.
[24] M. Vila,et al. Neurological diseases: Targeting programmed cell death in neurodegenerative diseases , 2003, Nature Reviews Neuroscience.
[25] A. Siderowf,et al. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. , 2004, Archives of neurology.
[26] S. Fahn. Levodopa-Induced Neurotoxicity , 1997 .
[27] J. Meerwaldt,et al. Factors that influence the occurrence of response variations in Parkinson's disease , 1987, Annals of neurology.
[28] O. Hornykiewicz. Brain neurotransmitter changes in Parkinson's disease , 1981 .
[29] W. Weiner. The initial treatment of Parkinson's disease should begin with levodopa , 1999, Movement disorders : official journal of the Movement Disorder Society.
[30] D. Brooks,et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. , 2000, The New England journal of medicine.
[31] Y. Agid. Levodopa: Is toxicity a myth? , 1998, Neurology.
[32] Joel S Perlmutter,et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. , 2002, Archives of neurology.
[33] D. Calne. Drugs for the Treatment of Parkinson’s Disease , 2011, Handbook of Experimental Pharmacology.
[34] S. Fahn. Is levodopa toxic? , 1996, Neurology.